ReviewFrontiers in cell and developmental biology2014
Cellular reprogramming for understanding and treating human disease.
Review in Frontiers in cell and developmental biology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Generation of oligodendrocyte precursor-like cells from mouse embryonic fibroblasts using miR-7a mimics.Iranian journal of basic medical sciences · 2026Article
- Unlocking Longevity in Aesthetic Dermatology: Epigenetics, Aging, and Personalized Care.International journal of dermatology · 2025Review
- The NADInternational journal of biological sciences · 2024Article
- Chemically modified mRNA beyond COVID-19: Potential preventive and therapeutic applications for targeting chronic diseases.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2022Review
- Disease-specific phenotypes in iPSC-derived neural stem cells with POLG mutations.EMBO molecular medicine · 2020Article
- Cell Reversal From a Differentiated to a Stem-Like State at Cancer Initiation.Frontiers in oncology · 2020Article
- Early Life Stress, Depression And Parkinson's Disease: A New Approach.Molecular brain · 2018Review
- RNAi-Based Techniques for the Analysis of Gene Function in Drosophila Germline Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2017Article
- Epigenetic Research of Neurodegenerative Disorders Using Patient iPSC-Based Models.Stem cells international · 2016Review
- DNA methyltransferase 1 mutations and mitochondrial pathology: is mtDNA methylated?Frontiers in genetics · 2015Article
- Potential of epigenetic therapies in the management of solid tumors.Cancer management and research · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the last two decades we have witnessed a paradigm shift in our understanding of cells so radical that it has rewritten the rules of biology. The study of cellular reprogramming has gone from little more than a hypothesis, to applied bioengineering, with the creation of a variety of important cell types. By way of metaphor, we can compare the discovery of reprogramming with the archeological discovery of the Rosetta stone. This stone slab made possible the initial decipherment of Egyptian hieroglyphics because it allowed us to see this language in a way that was previously impossible. We propose that cellular reprogramming will have an equally profound impact on understanding and curing human disease, because it allows us to perceive and study molecular biological processes such as differentiation, epigenetics, and chromatin in ways that were likewise previously impossible. Stem cells could be called "cellular Rosetta stones" because they allow also us to perceive the connections between development, disease, cancer, aging, and regeneration in novel ways. Here we present a comprehensive historical review of stem cells and cellular reprogramming, and illustrate the developing synergy between many previously unconnected fields. We show how stem cells can be used to create in vitro models of human disease and provide examples of how reprogramming is being used to study and treat such diverse diseases as cancer, aging, and accelerated aging syndromes, infectious diseases such as AIDS, and epigenetic diseases such as polycystic ovary syndrome. While the technology of reprogramming is being developed and refined there have also been significant ongoing developments in other complementary technologies such as gene editing, progenitor cell production, and tissue engineering. These technologies are the foundations of what is becoming a fully-functional field of regenerative medicine and are converging to a point that will allow us to treat almost any disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.